Skip to content
StockMarketAgent
Direct answer
MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $737, high $1308, with mid-point at $1016.
Stock analysis

MCK MCK fair value $737–$1,308

MCK
By StockMarketAgent.AI team· supervised by
Analiz edildi: 2026-05-13Sonraki güncelleme: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Fiyat
$725.17
▲ +290.95 (+40.12%)
Gerçeğe uygun değer
$1016
$737–$1308
Tavsiye
Güçlü Al
confidence 79/100
Yükseliş potansiyeli
+40.1%
upside to fair value
Güvenlik Marjı
$863.70
MoS level · 15%
Piyasa Değeri
$87.2B
P/E fwd 14.4
İngilizce yedekTR
Çeviri yapılırken İngilizce kaynak gösteriliyor
Bu rapor henüz çevrilmedi. Çeviri kuyruğu yetiştiğinde birkaç dakika sonra sayfayı yenileyin.

§1 Yönetici özeti

  • Composite fair value $1,016 with high case $1,308.
  • Implied upside of 40.1% to fair value.
  • Moat 9/10 · confidence 79/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$1,016
Margin of safety
+28.6%
Confidence
79/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$725.17Price
Low $737.34
Mid $1,016.12
High $1,307.92

MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Immense scale forming an entrenched
    Immense scale forming an entrenched oligopoly in US pharmaceutical distribution.
  • High barriers to entry due
    High barriers to entry due to extreme capital and regulatory requirements.
  • Cycle upside
    Aging demographics and expanded specialty drug approvals drive sustained volume growth.

§2 Olumsuz senaryo

A stress scenario combining severe legislative pressure on drug prices with a sustained high-interest-rate environment would squeeze margins. If operating margins dip below 1.0% and the WACCWACCWeighted average cost of capital. The blended after-tax discount rate applied to free cash flows in a DCF, reflecting both equity and debt financing costs. normalizes to a higher tier, intrinsic valueIntrinsic valueThe discounted present value of all cash a business will produce over its remaining life. The theoretical anchor for fair value, computed in practice as a range across explicit assumptions. regressions toward the $737 downside boundary.

Bu tezin bozulabileceği yollar

Major Retail Network Loss

· Low

The loss of a massive retail pharmacy network customer significantly impairs revenue volume and devastates operating leverage.

FV impact
-25%

Regulatory Margin Collapse

· Medium

Aggressive legislative action on drug pricing and PBM models compresses already razor-thin operating margins below 1.0%.

FV impact
-30%

Resurgent Litigation

· Low

Unexpected expansion of opioid-related liabilities or new mass torts drain free cash flow, threatening the share buyback program.

FV impact
-15%
İzlenecek erken uyarı sinyalleri
MetrikMevcutTetikleme eşiği
Operating margins slipping below 1.2% for consecutive quarters.MonitorDeterioration versus the report thesis
Cancellation or significant reduction of the annual share repurchase program.MonitorDeterioration versus the report thesis
Loss of major customer contracts in the retail pharmacy segment.MonitorDeterioration versus the report thesis
Slowing revenue growth in the higher-margin specialty oncology segment.MonitorDeterioration versus the report thesis
Deteriorating free cash flow conversion ratios.MonitorDeterioration versus the report thesis

§3 Mali geçmiş

Gelir tablosu — son altı dönem
KalemT−0T−1T−2T−3CAGR
Dönem2022-03-312023-03-312024-03-312025-03-31Trend
Gelir$263.97B$276.71B$308.95B$359.05B+10.8%
Brüt kâr$13.13B$12.36B$12.83B$13.32B+0.5%
Faaliyet kârı$2.59B$4.58B$4.17B$4.82B+22.9%
Net kâr$1.11B$3.56B$3.00B$3.30B+43.5%
EPS (sulandırılmış)$7.23$25.03$22.39$25.72+52.7%
EBITDA$2.87B$5.49B$4.68B$5.26B+22.4%
R&D
SG&A$10.54B$7.78B$8.66B$8.51B-6.9%

Kalite puanları

OCF / Net kâr
1.85×
>1 yüksek kazanç kalitesini gösterir
Muhasebe kalitesi kapısı
Fail
Sektöre göre ayarlanmış kapı
ROIC
68.7%
Yatırılan sermaye getirisi
Bölüm 3

Numbers analysis

Nakit akışı

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Sermaye tahsisi

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Bireysel aboneler — §4 ve sonrası11 bölüm daha

Tam analizi okuyun — 11 bölüm daha.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Kapsanan her sembol için tam rapor
24 ay tavsiye arşivi
İzleme listesi brifingleri + tavsiye değişiklik uyarıları
Herhangi bir dilde PDF + DOCX dışa aktarma
Ücretsiz denemeyi başlat
İstediğin zaman iptal edebilirsin.
FAQ

MCK — frequently asked questions

  1. Based on our latest analysis, MCK looks meaningfully undervalued. The current price is $725 versus a composite fair-value midpoint of $1016 (range $737–$1308), which implies roughly 40.1% upside to the midpoint.
Related coverage

Names readers of MCK also follow

Same archetype: mature-compounder